Marketing nod for Cipla's generic Nexavar in India as patent case hots up
This article was originally published in Scrip
Executive Summary
Cipla has received market authorisation for its generic version of Bayer's anticancer, Nexavar (sorafenib tosylate), in India, even as the two companies are locked in a strongly contested legal battle across Indian courts.